Rheumatoid arthritis
Conditions
Brief summary
DAS28
Detailed description
Number of swollen joints, Number of tender joints, HAQ, VAS pain, VAS general health, VAS fatigue, Doctor's global assessment, Number of individuals remaining on the designated drug (drug retention) including number of individuals prescribed biologic treatment, Number of patient´s contact with any health care giver, All other medications, including corticosteroids, other csDMARDs, biologics, intraarticular injections as well as change in dosage or administration route of methotrexate, ESR, CRP, Number of AE, Patients preferences, EQ5D, Gutmicrobiota, Questions on diet and alcohol consumption
Interventions
DRUGMETHOTREXATE
Sponsors
Region Vaesterbotten
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DAS28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of swollen joints, Number of tender joints, HAQ, VAS pain, VAS general health, VAS fatigue, Doctor's global assessment, Number of individuals remaining on the designated drug (drug retention) including number of individuals prescribed biologic treatment, Number of patient´s contact with any health care giver, All other medications, including corticosteroids, other csDMARDs, biologics, intraarticular injections as well as change in dosage or administration route of methotrexate, ESR, CRP, Number of AE, Patients preferences, EQ5D, Gutmicrobiota, Questions on diet and alcohol consumption | — |
Countries
Sweden
Outcome results
None listed